Curaleaf International, in Partnership with Jupiter Research, Secures EU Medical Device Certification for Europe’s First Handheld Liquid Inhalation Device
Curaleaf International, part of Curaleaf Holdings, Inc. (TSX:CURA) in collaboration with Jupiter Research LLC, a subsidiary of TILT Holdings Inc. (“TILT”) (Cboe CA: TILT) (OTCPK: TLLTF), has secured regulatory approval for the first handheld liquid inhalation device designed for precise medical cannabis administration. This EU medical device certification (Regulation (EU) 2017/745) paves the way for improved patient options and a new era of innovation in medical cannabis delivery.
The liquid inhalation device is now certified as a Class IIa medical device, meeting rigorous European regulatory standards. The device includes a magnetic snap-in cartridge and a rechargeable power supply, engineered to provide a consistent and controlled cannabinoid delivery.
A comprehensive technical file and full EU Declaration of Conformity were assessed and approved by a recognised EU Notified Body, validating the device’s quality, safety, and clinical robustness.
EU certification supports deployment in multiple global markets and, once commercialised, will enable healthcare professionals to recommend the device offered by Curaleaf International in countries including European countries, the UK, Canada, and regions across Australasia.
Boris Jordan, Chairman and CEO of Curaleaf, commented on this achievement: “Achieving EU medical certification is more than a regulatory milestone—it’s a signal that medical cannabis innovation is moving into the mainstream of global healthcare. We’re proud to offer a device that meets the highest standards of safety and quality, and we look forward to supporting patients and healthcare providers across Europe and beyond with a new, accurate and discrete option for treatment.”
Echoing this sentiment, TILT’s Chief Executive Officer Tim Conder, added: “Partnering with Curaleaf International on this project has been a natural extension of our long-standing partnership in the US. By delivering industry-leading, user-friendly solutions, our collaboration exemplifies how technology can revolutionise healthcare. Achieving EU medical certification on IP developed by our subsidiary Jupiter Research, validates the robustness of our engineering and R&D functions and sets a new benchmark for the industry.”
This development reinforces Curaleaf International’s role at the forefront of advancing access to legal, high-quality cannabis treatments across Europe and other international markets.
